QSI vs WAT
QSI: A proteomics instrumentation and consumables company bringing massively parallel single-molecule protein sequencing to researchers and clinicians through its Platinum platform, with a next-generation Proteus system in development. WAT: A leading global analytical instruments and life sciences company combining chromatography, mass spectrometry, and diagnostic solutions following a transformative $16.8 billion acquisition of BD's biosciences and diagnostics businesses.
Side-by-side fundamentals
| Metric | QSI | WAT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $0.80 | $370.82 | |
| Market cap as of 2026-07-23 | $174M | $35.9B | |
| P/E as of 2026-07-23 | n/a | 79.82 | |
| Net margin as of 2026-07-23 | -5605.9% | +11.9% | WAT higher |
| Gross margin as of 2026-07-23 | +40.0% | +55.1% | WAT higher |
| Operating margin as of 2026-07-23 | -6211.7% | +16.0% | WAT higher |
| ROE as of 2026-07-23 | -47.3% | +8.0% | WAT higher |
| ROA as of 2026-07-23 | -42.7% | +4.6% | WAT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.34 | QSI lower |
| Revenue growth (YoY) as of 2026-07-23 | -46.2% | +26.4% | WAT higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +2.1% | |
| Beta as of 2026-07-23 | 3.25 | 1.19 | |
| 1-year return as of 2026-07-22 close | -51.4% | +29.0% | WAT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.